TY - JOUR
T1 - Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel
AU - Lokhandwala, Juzar O.
AU - Best, Patricia J.M.
AU - Butterfield, Joseph H.
AU - Skelding, Kimberly A.
AU - Scott, Thomas
AU - Blankenship, James C.
AU - Buckley, Jeremy W.
AU - Berger, Peter B.
PY - 2009/8
Y1 - 2009/8
N2 - Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)
AB - Background-Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. Methods and Results-Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). Conclusions-In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. (Circ Cardiovasc Intervent. 2009;2:348-351.)
KW - Allergy
KW - Clopidogrel
KW - Cross-reactivity
KW - Hemorrhage
KW - Platelet aggregation inhibitors
KW - Thienopyridine
KW - Ticlopidine
UR - http://www.scopus.com/inward/record.url?scp=74549116585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74549116585&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.108.832964.108.832964
DO - 10.1161/CIRCINTERVENTIONS.108.832964.108.832964
M3 - Article
C2 - 20031738
AN - SCOPUS:74549116585
SN - 1941-7640
VL - 2
SP - 348
EP - 351
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 4
ER -